Researchers found that Splash Beverage Group is collaborating with Lupvindol Biosciences to develop CannEpil®, a cannabinoid-based product aimed at treating cancer and chronic pain in companion animals. This partnership is focused on navigating the FDA’s regulatory pathway for veterinary pharmaceuticals, starting with the Investigational New Animal Drug (INAD) process. The goal is to gain conditional approval for CannEpil, which could provide new treatment options for pets suffering from serious health issues.

This development is significant for pet owners who want to ensure their animals receive effective pain management and cancer care. With one in four dogs expected to develop cancer and millions of new diagnoses each year in the U.S., the need for innovative veterinary treatments is critical. If successful, CannEpil could offer a new, effective option for improving the quality of life for dogs facing these challenges.

The research is still in early stages, as the collaboration is just beginning to tackle the regulatory requirements set by the FDA. While the expertise of Lupvindol’s team, which has a history of bringing cannabinoid medicines to market, is promising, there is no guarantee that CannEpil will receive approval or that it will be effective. The project will require careful study design and regulatory compliance, with Splash retaining ownership of the resulting data and commercialization rights.

For pet owners interested in the potential benefits of cannabinoid treatments, staying informed about CannEpil’s progress could be worthwhile. While it’s too early to take action, being aware of emerging therapies may help you make informed decisions about your pet’s health in the future.

Source